$SNDX
Syndax Pharmaceuticals Inc

2020 Q2 Form 10-Q Financial Statement

#000156459020051287 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q3 2019 Q2
Revenue $379.0K $379.0K $379.0K
YoY Change 0.0% 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.050M $3.610M $3.460M
YoY Change 74.86% -12.59% -22.77%
% of Gross Profit
Research & Development $10.94M $9.923M $12.29M
YoY Change -10.96% -29.6% -17.24%
% of Gross Profit
Depreciation & Amortization $30.00K
YoY Change
% of Gross Profit
Operating Expenses $16.99M $13.53M $15.75M
YoY Change 7.85% -25.75% -18.5%
Operating Profit -$16.61M -$13.15M -$15.37M
YoY Change 8.04% -26.3% -18.87%
Interest Expense $638.0K $395.0K $501.0K
YoY Change 27.35% -19.06% 9.15%
% of Operating Profit
Other Income/Expense, Net -$452.0K $320.0K $458.0K
YoY Change -198.69% -36.38% -18.65%
Pretax Income -$17.06M -$12.83M -$14.92M
YoY Change 14.34% -26.01% -18.87%
Income Tax
% Of Pretax Income
Net Earnings -$17.06M -$12.83M -$14.92M
YoY Change 14.39% -26.01% -18.88%
Net Earnings / Revenue -4501.85% -3384.96% -3935.62%
Basic Earnings Per Share
Diluted Earnings Per Share -$420.1K -$405.6K -$472.0K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $189.7M $73.00M $83.70M
YoY Change 126.64% -20.22% -16.13%
Cash & Equivalents $53.73M $30.58M $26.67M
Short-Term Investments $136.1M $42.50M $57.00M
Other Short-Term Assets $1.900M $1.600M $1.900M
YoY Change 0.0% -60.98% -58.7%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $191.8M $74.85M $85.78M
YoY Change 123.61% -21.91% -18.07%
LONG-TERM ASSETS
Property, Plant & Equipment $700.0K $304.0K $327.0K
YoY Change 114.07% -23.23% -21.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $401.0K $201.0K
YoY Change -50.25% 78.22% -22.39%
Total Long-Term Assets $800.0K $1.531M $1.615M
YoY Change -50.46% 146.54% 139.61%
TOTAL ASSETS
Total Short-Term Assets $191.8M $74.85M $85.78M
Total Long-Term Assets $800.0K $1.531M $1.615M
Total Assets $192.6M $76.38M $87.39M
YoY Change 120.39% -20.82% -17.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M $6.757M $2.276M
YoY Change -20.91% 112.48% -57.03%
Accrued Expenses $9.100M $10.00M $13.70M
YoY Change -33.58% -18.7% 9.6%
Deferred Revenue $1.517M $1.517M
YoY Change 0.0% 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.50M $18.29M $17.49M
YoY Change -28.53% 7.51% -9.36%
LONG-TERM LIABILITIES
Long-Term Debt $19.90M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.60M $6.000K $7.000K
YoY Change 179900.0% -95.95% -97.75%
Total Long-Term Liabilities $32.50M $14.04M $14.62M
YoY Change 122.24% -7.47% -6.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.50M $18.29M $17.49M
Total Long-Term Liabilities $32.50M $14.04M $14.62M
Total Liabilities $45.00M $32.34M $32.12M
YoY Change 40.12% 0.45% -8.29%
SHAREHOLDERS EQUITY
Retained Earnings -$527.8M -$481.5M -$468.6M
YoY Change 12.62% 14.48% 16.22%
Common Stock $675.3M $525.5M $523.9M
YoY Change 28.91% 26274300.0% 10.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $147.6M $44.04M $55.28M
YoY Change
Total Liabilities & Shareholders Equity $192.6M $76.38M $87.39M
YoY Change 120.42% -20.82% -17.06%

Cashflow Statement

Concept 2020 Q2 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$17.06M -$12.83M -$14.92M
YoY Change 14.39% -26.01% -18.88%
Depreciation, Depletion And Amortization $30.00K
YoY Change
Cash From Operating Activities -$21.40M -$8.530M -$12.53M
YoY Change 70.79% -53.82% -17.29%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$78.62M $12.37M -$18.93M
YoY Change 315.32% 252.42% -198.18%
Cash From Investing Activities -$78.62M $12.37M -$18.93M
YoY Change 315.32% 252.42% -198.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $107.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 109.0M 80.00K 0.000
YoY Change -99.15% -100.0%
NET CHANGE
Cash From Operating Activities -21.40M -8.530M -12.53M
Cash From Investing Activities -78.62M 12.37M -18.93M
Cash From Financing Activities 109.0M 80.00K 0.000
Net Change In Cash 8.980M 3.920M -31.46M
YoY Change -128.54% -171.27% -843.74%
FREE CASH FLOW
Cash From Operating Activities -$21.40M -$8.530M -$12.53M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$8.530M -$12.53M
YoY Change -53.82% -17.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-11
us-gaap Net Income Loss
NetIncomeLoss
-42047000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3188000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30797000
us-gaap Interest Paid Net
InterestPaidNet
1133000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
126000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
226000
us-gaap Paid In Kind Interest
PaidInKindInterest
276000
us-gaap Share Based Compensation
ShareBasedCompensation
4480000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
62000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5193000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1138000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3959000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37885000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
68892000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
75077000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6185000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
19730000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
125000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
178000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28512000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Syndax Pharmaceuticals, Inc. (“we,” “us,” “our” or the “Company”) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in Delaware in 2005. We base our operations in Waltham, Massachusetts and we operate in one segment.</p>
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-56641000
us-gaap Net Income Loss
NetIncomeLoss
-52735000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42047000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39714490
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30103338
CY2020Q2 sndx Number Of Pre Funded Warrants Exchanged For Common Stock
NumberOfPreFundedWarrantsExchangedForCommonStock
280335
CY2020Q2 sndx Number Of Warrants Exercised In Cashless Exercise
NumberOfWarrantsExercisedInCashlessExercise
3489131
CY2020Q3 sndx Number Of Warrants Exercised In Cashless Exercise
NumberOfWarrantsExercisedInCashlessExercise
416666
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
55000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
36336000
CY2020Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
5567000
CY2019Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1297000
CY2020Q3 us-gaap Supplies
Supplies
145000
CY2019Q4 us-gaap Supplies
Supplies
166000
CY2020Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
228000
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
116000
CY2020Q3 sndx Reimbursable Costs
ReimbursableCosts
2000
CY2019Q4 sndx Reimbursable Costs
ReimbursableCosts
416000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
214000
CY2020Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
320000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
347000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7158000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2556000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1550000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7022000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4480000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
362000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
403000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2760000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2800000
CY2020Q3 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
5839000
CY2019Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
6726000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
470000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
266000
CY2020Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9431000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10195000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3063000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1550000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7022000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4480000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
311871
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3100000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25857
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000
CY2020Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
20006000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2285000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
9727000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7988000
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2020Q3 sndx Amortized Loss Reacquired Debt Noncurrent
AmortizedLossReacquiredDebtNoncurrent
217000
CY2020Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
211000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
31600000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1829000
CY2020Q1 sndx Stock Issued During Period Value Offering Expenses
StockIssuedDuringPeriodValueOfferingExpenses
93000
CY2020Q1 sndx Stock Issued During Period Value Direct Offering
StockIssuedDuringPeriodValueDirectOffering
24201000
CY2020Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrant Offering Expenses
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses
41000
CY2020Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrants From Direct Offering
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering
10665000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000
CY2020Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
64000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15236000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
53509000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2130000
CY2020Q2 sndx Stock Issued During Period Value Offering Expenses
StockIssuedDuringPeriodValueOfferingExpenses
7099000
CY2020Q2 sndx Stock Issued During Period Value Direct Offering
StockIssuedDuringPeriodValueDirectOffering
107901000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1015000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
69000
CY2020Q2 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
85000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-17062000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
147647000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3063000
CY2020Q3 sndx Offering Expenses Associated With Direct Offering
OfferingExpensesAssociatedWithDirectOffering
33000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1707000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-64000
CY2020Q3 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
94000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-20437000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
131977000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
53047000
CY2019Q1 sndx Stock Issued During Period Value At The Market Offering Expenses
StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
34000
CY2019Q1 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
830000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1592000
CY2019Q1 sndx Stock Issued During Period Value Direct Offering Common Stock Warrant
StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant
1571000
CY2019Q1 sndx Stock Issued During Period Value Offering Expenses
StockIssuedDuringPeriodValueOfferingExpenses
78000
CY2019Q1 sndx Stock Issued During Period Value Direct Offering
StockIssuedDuringPeriodValueDirectOffering
10922000
CY2019Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrant
StockIssuedDuringPeriodValuePreFundedCommonStockWarrant
1875000
CY2019Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrant Offering Expenses
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses
93000
CY2019Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrants From Direct Offering
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering
13032000
CY2019Q1 sndx Stock Issued During Period Value Common Stock Warrant With Direct Offering
StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering
3446000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33000
CY2019Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
26000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-14302000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
68626000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1338000
CY2019Q2 sndx Offering Expenses Associated With Direct Offering
OfferingExpensesAssociatedWithDirectOffering
20000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
CY2019Q2 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
46000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
151000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14916000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
55275000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1550000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-33000
CY2019Q3 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
53000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-12829000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
44043000
CY2019Q1 sndx Number Of Series Of Warrants
NumberOfSeriesOfWarrants
2
CY2019Q1 sndx Gross Proceeds From Offering
GrossProceedsFromOffering
27600000
CY2019Q1 sndx Offering Cost
OfferingCost
200000
CY2019Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P1Y4M24D
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3036719
CY2020Q1 sndx Adjustments To Additional Paid In Capital Repricing Warrants
AdjustmentsToAdditionalPaidInCapitalRepricingWarrants
3900000
CY2020Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P0Y4M24D
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6388889
CY2020Q2 sndx Offering Price Per Share
OfferingPricePerShare
18.00
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107900000
CY2020Q2 sndx Number Of Pre Funded Warrants Exchanged For Common Stock
NumberOfPreFundedWarrantsExchangedForCommonStock
280335
CY2020Q2 sndx Number Of Warrants Exercised In Cashless Exercise
NumberOfWarrantsExercisedInCashlessExercise
3489131
CY2020Q3 sndx Number Of Warrants Exercised In Cashless Exercise
NumberOfWarrantsExercisedInCashlessExercise
416666

Files In Submission

Name View Source Status
0001564590-20-051287-index-headers.html Edgar Link pending
0001564590-20-051287-index.html Edgar Link pending
0001564590-20-051287.txt Edgar Link pending
0001564590-20-051287-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-10q_20200930.htm Edgar Link pending
sndx-10q_20200930_htm.xml Edgar Link completed
sndx-20200930.xsd Edgar Link pending
sndx-20200930_cal.xml Edgar Link unprocessable
sndx-20200930_def.xml Edgar Link unprocessable
sndx-20200930_lab.xml Edgar Link unprocessable
sndx-20200930_pre.xml Edgar Link unprocessable
sndx-ex101_13.htm Edgar Link pending
sndx-ex311_8.htm Edgar Link pending
sndx-ex312_7.htm Edgar Link pending
sndx-ex321_9.htm Edgar Link pending